|
Oct 4
|
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
|
|
Oct 3
|
Immuron Full Year 2024 Earnings: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)
|
|
Jul 17
|
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
|
|
Jan 16
|
Immuron achieves record half yearly Travelan® sales
|
|
Dec 22
|
Immuron Clinical Trials Update
|
|
Dec 4
|
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
|
|
Nov 28
|
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
|
|
Aug 14
|
Immuron to present at the Military Health System Research Symposium
|